GALT
Galectin Therapeutics Inc
3.90$
-1.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +27.2% | -8.2% | +6.8% | +4.8% | -39.6% | -45.5% | +63.7% | -17.5% | +51.8% | -19.3% | -5.9% | |
| – | +28.2% | -8.1% | +7.2% | +5.1% | -39.8% | -46.2% | +66.1% | -17.5% | +52.7% | -19.3% | -6.6% | |
| – | +26.0% | -8.2% | +8.7% | +5.7% | -44.1% | -50.9% | +85.3% | -16.3% | +53.8% | -20.4% | -6.0% | |
| – | +26.0% | -8.2% | +8.7% | +5.7% | -44.1% | -50.9% | +85.3% | -16.3% | +53.8% | -20.4% | -6.0% | |
| – | +21.1% | +9.7% | +13.2% | +10.6% | -0.7% | +1.0% | +9.0% | +4.1% | +5.5% | +0.2% | +3.9% | |
| – | +49.0% | -19.4% | +15.7% | +72.8% | +40.2% | +213.0% | -90.3% | +1,166.4% | -94.1% | -9.0% | +1,975.0% | |
| – | +2.2% | +4.3% | -8.3% | +23,877.3% | +100.3% | +359.8% | -99.9% | +235,115.4% | -100.0% | -72.7% | +2,295,916.7% | |
| – | +139.9% | -41.0% | -2.6% | -24.4% | +102.4% | +15.5% | -10.2% | -8.1% | -39.8% | -3.8% | +19.4% | |
| – | +17.3% | +14.9% | +13.3% | +0.7% | -9.5% | -87.3% | +1,014.0% | – | – | +1.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.8% | +3.0% | +0.4% | +0.1% | +0.7% | +0.7% | +0.4% | +1.2% | -0.5% | +2.9% | +0.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.